

**Edition : JANVIER 2019**



- [1] **"Interpathologist Diagnostic Agreement for Non–Small Cell Lung Carcinomas Using Current and Recent Classifications,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [2] **"Eosinophilic Angiocentric Fibrosis: A Review and Update of Its Association With Immunoglobulin G4–Related Disease,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [3] **"Laboratory and Clinical Performance of the ADVIA Centaur Anticyclic Citrullinated Peptide Assay for Rheumatoid Arthritis Diagnosis,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [4] **"Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [5] **"Rhinoscleroma,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [6] **"Current Procedural Terminology Coding for Surgical Pathology: A Review and One Academic Center's Experience With Pathologist-Verified Coding,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [7] **"Pathology of Melanotic Schwannoma,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [8] **"Double-Equivocal HER2 Invasive Breast Carcinomas: Institutional Experience and Review of Literature,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [9] **"Current Issues in Surgical, Hematologic, and Cytologic Pathology,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [10] **"Pathology Consultation for the Gynecologic Oncologist: What the Surgeon Wants to Know,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [11] **"Hydatidiform Moles: Ancillary Techniques to Refine Diagnosis,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [12] **"Open-Source Whole Slide Image Preparation and Viewing Pipeline,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [13] **"Ovarian Sex Cord–Stromal Tumors: Reflections on a 40-Year Experience With a Fascinating Group of Tumors, Including Comments on the Seminal Observations of Robert E. Scully, MD,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [14] **"Are You a Doctor, Too?,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [15] **"Frontiers in Gynecologic Pathology,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [16] **"PAM50 and Pathologic Tumor Size,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.
- [17] **"NanoString System Versus Multiplex Fluorescent In Situ Hybridization for Gene Fusion Diagnosis in Lung Cancer Cytology Samples: Competing or Complementary Methods?,"** *Arch. Pathol. Lab. Med.*, Dec. 2018.



- [1] **"Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical features,"** *Histopathology*, Dec. 2018.
- [2] **"Oestrogen receptor can be expressed by normal and dysplastic anal squamous epithelia but only rarely by anal squamous cell carcinoma,"** *Histopathology*, Dec. 2018.
- [3] **"A morphological and molecular study of proposed early forms of traditional serrated adenoma,"** *Histopathology*, Dec. 2018.
- [4] **"Expression of T-cell receptor signalling pathway components in extranodal NK/T-cell lymphoma,"** *Histopathology*, Dec. 2018.
- [5] **"Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival,"** *Histopathology*, Dec. 2018.
- [6] **"Adenomatoid tumour of the uterus is frequently associated with iatrogenic immunosuppression,"** *Histopathology*, Dec. 2018.
- [7] **"Concordance of PD-L1 expression in matched urothelial bladder cancer specimens,"** *Histopathology*, Dec. 2018.
- [8] **"Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?,"** *Histopathology*, Dec. 2018.
- [9] **"Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy,"** *Histopathology*, Dec. 2018.
- [10] **"Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations,"** *Histopathology*, Dec. 2018.
- [11] **"The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases,"** *Histopathology*, Dec. 2018.
- [12] **"Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion,"** *Histopathology*, Dec. 2018.
- [13] **"Impact of breast cancer grade discordance on prediction of outcome,"** *Histopathology*, Dec. 2018.
- [14] **"MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma,"** *Histopathology*, Dec. 2018.
- [15] **"Dichotomous histopathological assessment of ductal carcinoma *in situ* of the breast results in substantial interobserver concordance,"** *Histopathology*, Dec. 2018.
- [16] **"Maspin mRNA expression in sentinel lymph nodes predicts non-SLN metastasis in breast cancer patients with SLN metastasis,"** *Histopathology*, Dec. 2018.

- [17] **"Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance,"** *Histopathology*, Dec. 2018.
- [18] **"Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management,"** *Histopathology*, Dec. 2018.



- [1] **"PIN-like (Ductal) Adenocarcinoma of the Prostate,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [2] **"Tumor Grade Is Prognostically Relevant Among Mismatch Repair Deficient Colorectal Carcinomas,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [3] **"Recurrent Mutations in APC and CTNNB1 and Activated Wnt/ $\beta$ -catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [4] **"Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [5] **"Inflammation, Active Fibroplasia, and End-stage Fibrosis in 172 Biliary Atresia Remnants Correlate Poorly With Age at Kasai Portoenterostomy, Visceral Heterotaxy, and Outcome,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [6] **"Pathologic Subtypes of Lung Adenocarcinoma Brain Metastasis Is a Strong Predictor of Survival After Resection,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [7] **"SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [8] **"Refined Criteria for Separating Low-grade Dysplasia and Nondysplastic Barrett Esophagus Reduce Equivocal Diagnoses and Improve Prediction of Patient Outcome,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [9] **"A Clinicopathologic and Molecular Analysis of 34 Mediastinal Germ Cell Tumors Suggesting Different Modes of Teratoma Development,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [10] **"VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney.,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [11] **"Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [12] **"Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [13] **"Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma,"** *Am. J. Surg. Pathol.*, Dec. 2018.
- [14] **"'Atrophic Kidney'-like Lesion,"** *Am. J. Surg. Pathol.*, Dec. 2018.

[15] **“Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer,”** *Am. J. Surg. Pathol.*, Dec. 2018.

## Journal of Clinical Oncology®

An American Society of Clinical Oncology Journal

[1] **“Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light,”** *J. Clin. Oncol.*, Dec. 2018.

[2] **“Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What’s Next?,”** *J. Clin. Oncol.*, Dec. 2018.

[3] **“Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy,”** *J. Clin. Oncol.*, Dec. 2018.

[4] **“Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation,”** *J. Clin. Oncol.*, Dec. 2018.

[5] **“Epidemiology and Risk Factors for Kidney Cancer,”** *J. Clin. Oncol.*, Dec. 2018.

[6] **“Imaging Advances in the Management of Kidney Cancer,”** *J. Clin. Oncol.*, Dec. 2018.

[7] **“Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management,”** *J. Clin. Oncol.*, Dec. 2018.

[8] **“Prognostication in Kidney Cancer: Recent Advances and Future Directions,”** *J. Clin. Oncol.*, Dec. 2018.

[9] **“Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers,”** *J. Clin. Oncol.*, Dec. 2018.

[10] **“The Immunobiology of Kidney Cancer,”** *J. Clin. Oncol.*, Dec. 2018.

[11] **“Chromosome 3p Loss–Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma,”** *J. Clin. Oncol.*, Dec. 2018.

[12] **“Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions,”** *J. Clin. Oncol.*, Dec. 2018.

[13] **“Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma,”** *J. Clin. Oncol.*, Dec. 2018.

[14] **“Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing,”** *J. Clin. Oncol.*, Dec. 2018.

[15] **“Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected *BRAF* V600–Mutant Stage III Melanoma,”** *J. Clin. Oncol.*, Dec. 2018.

[16] **“Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guidelines by ASCO/ College of American Pathologists Will Reduce False-Positive Tests,”** *J. Clin. Oncol.*, Dec. 2018.

[17] **“Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution,”** *J. Clin. Oncol.*, Dec. 2018.

- [18] **“Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline,”** *J. Clin. Oncol.*, Jun. 2018.
- [19] **“Prophylactic Cranial Irradiation in Stage III Non–Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point,”** *J. Clin. Oncol.*, Dec. 2018.
- [20] **“Associations of Pre- and Postdiagnosis Diet Quality With Risk of Mortality Among Men and Women With Colorectal Cancer,”** *J. Clin. Oncol.*, Dec. 2018.
- [21] **“Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry,”** *J. Clin. Oncol.*, Dec. 2018.
- [22] **“Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study,”** *J. Clin. Oncol.*, Dec. 2018.

## JAMA Oncology

- [1] **“Association of Low Nodal Positivity Rate Among Patients With *ERBB2* -Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy,”** *JAMA Surg.*, Dec. 2018.
- [2] **“Survival Outcomes in Patients With Previously Untreated *BRAF* Wild-Type Advanced Melanoma Treated With Nivolumab Therapy,”** *JAMA Oncol.*, Oct. 2018.
- [3] **“Focus on the Number of Radiation Oncology Trials or on Clinical Relevance—Reply,”** *JAMA Oncol.*, Dec. 2018.
- [4] **“Focus on the Number of Radiation Oncology Trials or on Clinical Relevance?,”** *JAMA Oncol.*, Dec. 2018.
- [5] **“Moving Precision Oncology Forward Amid Myths and Misconceptions—Reply,”** *JAMA Oncol.*, Dec. 2018.
- [6] **“Moving Precision Oncology Forward Amid Myths and Misconceptions,”** *JAMA Oncol.*, Dec. 2018.
- [7] **“Moving Precision Oncology Forward Amid Myths and Misconceptions,”** *JAMA Oncol.*, Dec. 2018.
- [8] **“Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply,”** *JAMA Oncol.*, Dec. 2018.
- [9] **“*MUC16* Mutations and Prognosis in Gastric Cancer,”** *JAMA Oncol.*, Dec. 2018.
- [10] **“Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer,”** *JAMA Oncol.*, Dec. 2018.
- [11] **“Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening,”** *JAMA Oncol.*, Dec. 2018.
- [12] **“Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer,”** *JAMA Oncol.*, Dec. 2018.

- [13] **“Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors,”** *JAMA Oncol.*, Dec. 2018.
- [14] **“Targeted Alpha Therapy, an Emerging Class of Cancer Agents,”** *JAMA Oncol.*, Dec. 2018.
- [15] **“Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor,”** *JAMA Oncol.*, Dec. 2018.
- [16] **“Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors,”** *JAMA Oncol.*, Dec. 2018.
- [17] **“Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer,”** *JAMA Oncol.*, Dec. 2018.
- [18] **“Association of *MUC16* Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer,”** *JAMA Oncol.*, Dec. 2018.
- [19] **“Association Between Aspirin Use and Risk of Hepatocellular Carcinoma,”** *JAMA Oncol.*, Dec. 2018.
- [20] **“Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies,”** *JAMA Oncol.*, Dec. 2018.

## ANNALS OF ONCOLOGY

- [1] **“Identification of a novel crizotinib-sensitive *MET–ATXN7L1* gene fusion variant in lung adenocarcinoma by next generation sequencing,”** *Ann. Oncol.*, Dec. 2018.
- [2] **“Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial,”** *Ann. Oncol.*, Dec. 2018.
- [3] **“Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue,”** *Ann. Oncol.*, Dec. 2018.
- [4] **“A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial,”** *Ann. Oncol.*, Dec. 2018.
- [5] **“Repeated mut *KRAS* ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer,”** *Ann. Oncol.*, Dec. 2018.
- [6] **“Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach,”** *Ann. Oncol.*, Dec. 2018.
- [7] **“Novel therapies in urothelial carcinoma: a biomarker-driven approach,”** *Ann. Oncol.*, Dec. 2018.
- [8] **“*KRAS* mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer,”** *Ann. Oncol.*, Dec. 2018.
- [9] **“More accurate prognostic prediction in diffuse large B-cell lymphoma: beyond cell-of-origin,”** *Ann. Oncol.*, Dec. 2018.

- [10] **“Carboplatin in the neoadjuvant treatment of triple-negative breast cancer—ready for prime time?,”** *Ann. Oncol.*, Dec. 2018.
- [11] **“CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?,”** *Ann. Oncol.*, Dec. 2018.

## MODERN PATHOLOGY

- [1] **“Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53.,”** *Mod. Pathol.*, Nov. 2018.
- [2] **“Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms.,”** *Mod. Pathol.*, Nov. 2018.
- [3] **“Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.,”** *Mod. Pathol.*, Nov. 2018.
- [4] **“Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.,”** *Mod. Pathol.*, Dec. 2018.
- [5] **“Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.,”** *Mod. Pathol.*, Dec. 2018.
- [6] **“Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.,”** *Mod. Pathol.*, Dec. 2018.
- [7] **“Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience.,”** *Mod. Pathol.*, Nov. 2018.
- [8] **“Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin.,”** *Mod. Pathol.*, Nov. 2018.
- [9] **“Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions.,”** *Mod. Pathol.*, Nov. 2018.
- [10] **“Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.,”** *Mod. Pathol.*, Nov. 2018.
- [11] **“Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing.,”** *Mod. Pathol.*, Nov. 2018.
- [12] **“Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases.,”** *Mod. Pathol.*, Dec. 2018.
- [13] **“HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions.,”** *Mod. Pathol.*, Dec. 2018.
- [14] **“Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification.,”** *Mod. Pathol.*, Dec. 2018.

- [15] **"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal,"** *Mod. Pathol.*, Dec. 2018.
- [16] **"hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality,"** *Mod. Pathol.*, Dec. 2018.
- [17] **"Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency,"** *Mod. Pathol.*, Dec. 2018.
- [18] **"Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association,"** *Mod. Pathol.*, Dec. 2018.
- [19] **"Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus,"** *Mod. Pathol.*, Dec. 2018.
- [20] **"Lipoblastoma-like tumor of the vulva: a clinicopathologic, immunohistochemical, fluorescence in situ hybridization and genomic copy number profiling study of seven cases,"** *Mod. Pathol.*, Dec. 2018.





Leading the way in experimental and clinical research in hematology

- [1] **“Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells,”** *Blood*, Dec. 2018.
- [2] **“Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse,”** *Blood*, Dec. 2018.
- [3] **“CREBBP gene mutations are frequently detected in in situ follicular neoplasia,”** *Blood*, Dec. 2018.
- [4] **“The genomic landscape of plasma cells in systemic light chain amyloidosis,”** *Blood*, Dec. 2018.
- [5] **“Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!”** *Blood*, Dec. 2018.